Cargando…
Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer.
Two hundred and eleven patients with node-positive stage II and III breast cancer were treated with eight cycles of adjuvant chemotherapy comprising cyclophosphamide, doxorubicin and oral ftorafur (CAFt), with and without tamoxifen. All patients had undergone radical surgery, and 148 patients were t...
Autores principales: | Saarto, T., Blomqvist, C., Rissanen, P., Auvinen, A., Elomaa, I. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063283/ https://www.ncbi.nlm.nih.gov/pubmed/9010042 |
Ejemplares similares
-
Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF
por: Poikonen, P, et al.
Publicado: (1999) -
The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial.
por: Blomqvist, C., et al.
Publicado: (1992) -
Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
por: Saarto, T., et al.
Publicado: (1997) -
Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids
por: Vehmanen, L, et al.
Publicado: (2004) -
Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients.
por: Saarto, T., et al.
Publicado: (1998)